Apnimed, Inc. APMD
16.92 USD +0.29 (+1.74%)
Regular-session close
16.92 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
16.38 Day range 17.46
14.16 52-week range 32.55
- YTD
- -32.32%
- 1 year
- -32.32%
News
seekingalpha.com Apnimed: Top Pick Biotech, Treating OSA With A Pill, Initiating With A Buy I initiate Apnimed with a 'Buy' rating and a $42 price target, citing mispriced FDA risk for Oxnimbi (AD109). Both Phase 3 trials met primary endpoints; NDA accepted with February 28, 2027 PDUFA…
globenewswire.com Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and…
globenewswire.com Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026 CHEST-led panel to showcase data from the Phase 3 SynAIRgy and LunAIRo trials, exploring potential new paradigms for advancing OSA patient management CHEST-led panel to showcase data from the Phase 3…
globenewswire.com Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and…
defenseworld.net Apnimed, Inc. (NASDAQ:APMD) Stock Short Interest Jumps 55.7% Apnimed, Inc. (NASDAQ: APMD - Get Free Report) saw a significant increase in short interest in the month of September. As of September 15th, there was short interest totaling 879,684 shares, an…
defenseworld.net Apnimed, Inc. (NASDAQ:APMD) Given Consensus Rating of “Moderate Buy” by Brokerages Shares of Apnimed, Inc. (NASDAQ: APMD - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are covering the firm, MarketBeat.com reports. One…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47%…
seekingalpha.com Apnimed: What We Know Heading Into The Feb PDUFA Apnimed, Inc. (APMD) is a late-stage, de-risked regulatory play with a fully funded path to commercialisation, focused on AD109 for obstructive sleep apnea (OSA). AD109 (Oxnimbi) demonstrated robust…benzinga.com Apnimed Q2 EPS $3.91 Beats $(0.34) Estimate, Sales $12.080M Apnimed (NASDAQ:APMD) reported quarterly earnings of $3.91 per share which beat the analyst consensus estimate of $(0.34) by 1250 percent. The company reported $12.080 million in sales this quarter.
globenewswire.com Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and…
globenewswire.com Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late stage clinical pharmaceutical company dedicated to the discovery, development…
defenseworld.net Apnimed, Inc.’s Quiet Period Will End on September 9th (NASDAQ:APMD) Apnimed's (NASDAQ: APMD - Get Free Report) quiet period is set to expire on Wednesday, September 9th. Apnimed had issued 12,000,000 shares in its public offering on July 31st. The total size of the…
proactiveinvestors.com Apnimed shares surge on bullish BofA initiation Shares of Apnimed rose 8% Tuesday after BofA Securities initiated coverage of the company with a Buy rating and a $41 price target. The rating is based on a risk-adjusted discounted cash flow…benzinga.com LifeSci Capital Initiates Coverage On Apnimed with Outperform Rating, Announces Price Target of $50 LifeSci Capital analyst Francois Brisebois initiates coverage on Apnimed (NASDAQ:APMD) with a Outperform rating and announces Price Target of $50.
benzinga.com This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiations. Coverage initiated on various stocks.benzinga.com Cantor Fitzgerald Initiates Coverage On Apnimed with Overweight Rating, Announces Price Target of $60 Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Apnimed (NASDAQ:APMD) with a Overweight rating and announces Price Target of $60.
benzinga.com B of A Securities Initiates Coverage On Apnimed with Buy Rating, Announces Price Target of $41 B of A Securities analyst Jason Gerberry initiates coverage on Apnimed (NASDAQ:APMD) with a Buy rating and announces Price Target of $41.
247wallst.com Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks The Nasdaq debut of Apnimed (NASDAQ:APMD) has given public investors their first pure-play bet on a pill for obstructive sleep apnea (OSA).
globenewswire.com Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and…
benzinga.com AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lower in pre-market trading.
benzinga.com Why Atkore Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket Atkore Inc (ATKR) shares rise on strong Q3 results and acquisition by Prysmian for $95.00 per share. Other gainers include UPC, YYAI, RITR, FCUV, SGLY, FNGR, ALAR, FERG, and BMY while FMFC, PWCM,…
reuters.com Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO Late-stage drug developer Apnimed is targeting a valuation of up to $608 million in its initial public offering in the United States.
seekingalpha.com Apnimed Seeks IPO For OSA Treatment Commercialization Apnimed, Inc. is pursuing an IPO to fund regulatory approval and initial commercialization of its lead OSA drug, Oxnimbi (AD109). AD109 has shown strong efficacy in Phase 3 trials and an FDA decision…
